(Q33830384)

English

Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

Europe PubMed Central

Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Daniel J. Diekema

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Maiken C Arendrup

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Michael A. Pfaller

1

object named as

M A Pfaller

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

S D Brown

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

S R Lockhart

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

M Motyl

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

D S Perlin

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

CLSI Subcommittee for Antifungal Testing

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

24 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Drug Resistance Updates

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

164-176

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21353623%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

W-1 solubilization and kinetics of inhibition by cilofungin of Candida albicans (1,3)-beta-D-glucan synthase

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Efficacy of caspofungin in invasive candidiasis and candidemia--de-escalation strategy

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Cloning of the RHO1 gene from Candida albicans and its regulation of beta-1,3-glucan synthesis

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Anidulafungin: an echinocandin antifungal

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Anidulafungin: a new echinocandin with a novel profile

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Potential confusion regarding the term 'resistance' in epidemiological surveys

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Caspofungin: the first in a new class of antifungal agents

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Breakthrough invasive candidiasis in patients on micafungin

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Candida spp. bloodstream infection: influence of antifungal treatment on outcome.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Micafungin activity against Candida albicans with diverse azole resistance phenotypes

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Pharmacology of Systemic Antifungal Agents

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Treatment of invasive candidiasis with echinocandins

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Setting and revising antibacterial susceptibility breakpoints

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Caspofungin disk diffusion breakpoints and quality control

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Caspofungin for invasive candidiasis at a tertiary care medical center

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Micafungin: a new echinocandin

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Echinocandin inhibition of 1,3-β-D-glucan synthase from Candida albicans

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

EUCAST technical note on fluconazole

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Resistance to echinocandin-class antifungal drugs

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Caspofungin-non-susceptible Candida isolates in cancer patients

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Acquired resistance to echinocandins in Candida albicans: case report and review

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Antifungal drug resistance: do molecular methods provide a way forward?

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

The echinocandins: three useful choices or three too many?

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

The echinocandins

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Novel FKS mutations associated with echinocandin resistance in Candida species

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Breakpoints for susceptibility testing should not divide wild-type distributions of important target species

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Epidemiology of invasive candidiasis: a persistent public health problem

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Echinocandins: role in antifungal therapy, 2005.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Fungal ß(1,3)-D-glucan synthesis

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based Surveillance

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Anidulafungin versus fluconazole for invasive candidiasis

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.DRUP.2011.01.004

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33830384&oldid=1959536589"